Microdosing a GLP-1 means taking less of it than the trials used. That can be a sound clinical decision, a cheaper way in, or a marketing device — and the same provider will often sell you all three at once without distinguishing between them.
The word arrived from a different context entirely, and it carries connotations it has not earned here. In GLP-1 care it simply means a dose below the standard titration schedule: 0.1 mg of semaglutide rather than the 0.25 mg starting step, or 1 mg of tirzepatide rather than 2.5 mg. Nothing more sophisticated is implied.
Providers are moving toward it quickly, because it solves two commercial problems at once. It lowers the entry price at a moment when compounded pricing has collapsed and margins with it, and it reduces the side effects that drive people off treatment in the first six weeks. Both of those are real benefits. The problem is the third claim that tends to travel alongside them.
What the dose ladder actually looks like
GLP-1 dosing is a staircase, and the lower steps were never meant to do the work. In the semaglutide trials, 0.25 mg weekly exists to let your gut adapt — it is a tolerance step, not a treatment dose. The weight loss everybody has read about came from people who climbed to 2.4 mg and stayed there.
Where a dose sits on the studied ladder
Move the slider to see whether a dose is one the weight-loss trials actually used. Doses below the studied range may still suit you — they simply have no trial result attached.
Standard titration step
Standard schedule: Weeks 1–4
The standard starting dose. Intended to build tolerance, not to produce weight loss.
In the trial programme behind Wegovy, adults reached a 2.4 mg weekly maintenance dose and lost an average of about 15% of body weight over 68 weeks.
Titration schedules are the standard ones for the approved products and are shown for orientation, not as a dosing instruction. Compounded products are not FDA-approved and your prescriber sets your schedule. Never change a dose on the basis of a web page.
That distinction is where microdosing marketing gets slippery. A provider advertising a microdose plan beside the familiar figures — 15% of body weight with semaglutide, around 20% with tirzepatide — is borrowing results from doses its plan does not reach.
When a lower dose is the right call
There are genuinely good reasons to sit below the standard schedule, and it would be wrong to dismiss the whole practice.
- You cannot tolerate standard titration. Nausea, vomiting and diarrhoea concentrate in the days after each dose increase. A dose you keep taking beats a dose you abandon in week five.
- You are maintaining rather than losing. Once you have reached a goal weight, the dose required to hold it may be lower than the one that got you there.
- You are managing a specific side effect. Slowing the climb, or stepping back down a rung, is a normal clinical response to a bad reaction.
- You have a clinical reason to go slowly — significant gastrointestinal history, or medications that interact with delayed gastric emptying.
Every one of those is a decision for a clinician who knows your history. None of them is a pricing tier you should select from a menu before anyone has assessed you.
When it is a price tier wearing a clinical coat
Look at how the option is presented. If a microdose plan appears in a pricing grid as the cheapest row, selectable before any clinical assessment, it is functioning as a price point. If it appears as something your clinician proposes after reviewing your intake, it is functioning as medicine.
Some providers are honest about this and deserve credit. Fella Health labels its microdose tier as "not for weight loss" — a plainer statement than most of this industry manages. Measured publishes its microdose plan at $79 a month and describes it as a weekly lower dose rather than implying equivalence.
Others are less clear. Where a provider's compounded offering is microdose-only, the important question is what maximum dose the programme will actually take you to, and you should ask it before enrolling rather than discovering the ceiling at month four.
How microdose plans are positioned across providers we have verified
| Provider | Published price | How it is framed | What to ask |
|---|---|---|---|
| Measured | $79/mo | A weekly lower-dose option in a 14-line catalogue | What is the maximum dose available if you want to escalate |
| Lemonaid Health | $199/mo | A microdose tier beside standard plans at $229–$299 | Whether switching to standard dosing changes the price |
| Noom Med | $179/mo | Its compounded GLP-1 offering is the microdose programme | What dose ceiling the programme reaches |
| Remedy Meds | Not published | A twice-weekly microdose plan alongside standard options | That switching to microdosing voids its weight-loss warranty |
| Fella Health | Not published | Labelled explicitly as not for weight loss | Nothing — this framing is accurate |
Scroll the table sideways to see every column.
The cost question, done properly
A microdose plan is cheaper per month. Whether it is cheaper per outcome is a different calculation, and nobody can do it for you honestly, because the outcome at those doses has not been characterised.
What can be compared is the alternative. At $79 a month, Measured's microdose is genuinely the cheapest published GLP-1 line we have verified. But standard-dose compounded semaglutide starts at $79 a month equivalent on a 12-month CoreAge Rx plan with no membership. That matches the recorded microdose headline while requiring a different commitment and clinical plan.
What it actually costs per year
Advertised prices in this category are usually medication only. Add the membership back in and the ranking changes. Pick a provider, or enter the quote you were given.
One-month semaglutide rate. Starting at $79/month equivalent requires a 12-month plan ($948 total); confirm payment and renewal terms.
- First month
- $139
- Every month after
- $139
- Total over 12 months
- $1,668
No membership on this plan, so every dollar goes to medication and care.
Figures are the providers' own published prices as of our last review of each. Promotional rates, multi-month prepayment and dose changes can all move these numbers — confirm at checkout.
What to ask before starting a microdose plan
- What maximum dose does this programme reach, and does the price change when I escalate?
- Is this being recommended because of my clinical picture, or because it is the entry-level tier?
- What would standard titration cost with you, and with a provider that publishes dose-flat pricing?
- If I do not respond at this dose by month three, what is the plan?
- Does choosing this tier affect any guarantee or refund terms?
- Who is monitoring the response, and how often will we actually review it?
The honest summary
Microdosing is not a scam and it is not a shortcut. It is a lower dose, with a better side-effect profile, a lower price, and no trial data behind it for weight loss. For someone who cannot tolerate standard titration, that trade is obviously worth making. For someone choosing it from a pricing page because it is the cheapest row, it is a trade being made without anyone naming it.
If your reason for considering it is cost, check the full-dose market first — it has moved a long way down, and the difference may be smaller than you expect. If your reason is tolerance, that is a conversation with a clinician, and a good provider will have it with you rather than selling you a tier.